Opaleye Management Holds Stake in Chimerix (CMRX); As Jpmorgan Chase & Co Com (JPM) Shares Declined, Palladium Partners Trimmed by $793,557 Its Position

Chimerix, Inc. (NASDAQ:CMRX) Logo

Opaleye Management Inc increased its stake in Chimerix Inc (CMRX) by 70.46% based on its latest 2018Q4 regulatory filing with the SEC. Opaleye Management Inc bought 835,000 shares as the company’s stock declined 33.53% while stock markets rallied. The hedge fund held 2.02 million shares of the health care company at the end of 2018Q4, valued at $5.19 million, up from 1.19M at the end of the previous reported quarter. Opaleye Management Inc who had been investing in Chimerix Inc for a number of months, seems to be bullish on the $104.35 million market cap company. The stock increased 3.54% or $0.07 during the last trading session, reaching $2.05. About 610,059 shares traded or 37.36% up from the average. Chimerix, Inc. (NASDAQ:CMRX) has declined 52.97% since March 17, 2018 and is downtrending. It has underperformed by 57.34% the S&P500. Some Historical CMRX News: 29/03/2018 – CHIMERIX INC – MARIO IS RETIRING AS OF CHIMERIX 2018 ANNUAL MEETING OF STOCKHOLDERS IN JUNE; 29/03/2018 – CHIMERIX INC – MARTHA WILL SUCCEED ERNEST MARIO; 29/03/2018 – CHIMERIX INC CMRX.O SAYS MARTHA J. DEMSKI APPOINTED CHAIRMAN OF THE BOARD; 14/05/2018 – Morgan Stanley & International Buys 1.7% Position in Chimerix; 08/03/2018 Chimerix Forms Golden Cross: Technicals; 29/03/2018 – Chimerix Announces Martha J. Demski as Board Chair; 19/03/2018 – The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Corr; 29/03/2018 – Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors; 20/04/2018 – DJ Chimerix Inc, Inst Holders, 1Q 2018 (CMRX); 07/05/2018 – Chimerix 1Q Loss/Shr 42c

Palladium Partners Llc decreased its stake in Jpmorgan Chase & Co Com (JPM) by 2.27% based on its latest 2018Q4 regulatory filing with the SEC. Palladium Partners Llc sold 8,181 shares as the company’s stock declined 6.08% while stock markets rallied. The institutional investor held 352,966 shares of the major banks company at the end of 2018Q4, valued at $34.46 million, down from 361,147 at the end of the previous reported quarter. Palladium Partners Llc who had been investing in Jpmorgan Chase & Co Com for a number of months, seems to be less bullish one the $348.98 billion market cap company. The stock increased 1.15% or $1.21 during the last trading session, reaching $106.55. About 24.81M shares traded or 63.12% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has declined 8.15% since March 17, 2018 and is downtrending. It has underperformed by 12.52% the S&P500. Some Historical JPM News: 13/04/2018 – JPMorgan Chase Sees 2018 Noninterest Revenue Growth About 7%, Market Dependent; 13/04/2018 – JPMORGAN CHASE & CO – Q18 RESULTS INCLUDED $505 MILLION (PRETAX) MARK-TO-MARKET GAINS; 26/04/2018 – INTEGRA LIFESCIENCES HOLDINGS CORP IART.O : JP MORGAN RAISES TARGET PRICE TO $57 FROM $55; 03/05/2018 – Bank of America, JPMorgan Chase and Citigroup are among a group of banks that banned credit card purchases for digital currency in February; 23/03/2018 – JPMORGAN SAYS UK AVERAGE GENDER PAY GAP IS 36%; 07/03/2018 – UNITE GROUP PLC UTG.L : JP MORGAN RAISES TARGET PRICE TO 900P FROM 850P; 18/05/2018 – SWISS LIFE HOLDING AG SLHN.S : JP MORGAN RAISES TARGET PRICE TO SFR 370 FROM SFR 350; 12/04/2018 – JPMORGAN CHASE & CO. DISCLOSES A 5.30 PCT STAKE IN PRAIRIE MINING LTD – FILING; 15/05/2018 – U.S. Cellular Presenting at JPMorgan Conference Tomorrow; 14/05/2018 – JPMorgan Global Monetary Policy Forecasts as of May 11 (Table)

More notable recent Chimerix, Inc. (NASDAQ:CMRX) news were published by: Benzinga.com which released: “Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering – Benzinga” on February 20, 2019, also Globenewswire.com with their article: “Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results – GlobeNewswire” published on March 05, 2019, Seekingalpha.com published: “Midday movers and shakers – Seeking Alpha” on March 05, 2019. More interesting news about Chimerix, Inc. (NASDAQ:CMRX) were released by: Finance.Yahoo.com and their article: “The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings – Yahoo Finance” published on March 05, 2019 as well as Benzinga.com‘s news article titled: “Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings – Benzinga” with publication date: March 08, 2019.

Investors sentiment decreased to 1.35 in Q4 2018. Its down 0.06, from 1.41 in 2018Q3. It dived, as 8 investors sold CMRX shares while 23 reduced holdings. 17 funds opened positions while 25 raised stakes. 36.13 million shares or 1.15% less from 36.56 million shares in 2018Q3 were reported. Leisure Capital Management stated it has 0.06% in Chimerix, Inc. (NASDAQ:CMRX). Royal Bank & Trust Of Canada invested in 600 shares or 0% of the stock. 3.56 million were reported by Redmile Gp Inc Limited Liability Corporation. Axa holds 319,073 shares. Citadel Limited Liability Com owns 48,135 shares. Tiaa Cref Management Ltd Co holds 0% in Chimerix, Inc. (NASDAQ:CMRX) or 79,934 shares. California State Teachers Retirement Systems has invested 0% of its portfolio in Chimerix, Inc. (NASDAQ:CMRX). Morgan Stanley has invested 0% in Chimerix, Inc. (NASDAQ:CMRX). Bridgeway Capital Mgmt has 179,200 shares. Hrt Ltd Liability Corp holds 15,759 shares or 0.01% of its portfolio. Deutsche Retail Bank Ag, Germany-based fund reported 258,033 shares. The Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Chimerix, Inc. (NASDAQ:CMRX). State Of Wisconsin Investment Board reported 0% in Chimerix, Inc. (NASDAQ:CMRX). Moreover, Arrowmark Colorado Ltd Liability has 0.13% invested in Chimerix, Inc. (NASDAQ:CMRX). Legal General Group Incorporated Plc reported 0% stake.

Opaleye Management Inc, which manages about $151.96 million and $267.98 million US Long portfolio, decreased its stake in Deciphera Pharmaceuticals In by 80,000 shares to 340,000 shares, valued at $7.14M in 2018Q4, according to the filing. It also reduced its holding in Polarityte Inc by 365,000 shares in the quarter, leaving it with 400,000 shares, and cut its stake in Amarin Corp Plc (NASDAQ:AMRN).

Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on April, 12. They expect $2.35 EPS, down 0.84% or $0.02 from last year’s $2.37 per share. JPM’s profit will be $7.70 billion for 11.34 P/E if the $2.35 EPS becomes a reality. After $1.98 actual EPS reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts 18.69% EPS growth.

Palladium Partners Llc, which manages about $1.69 billion and $1.25 billion US Long portfolio, upped its stake in Emerson Elec Co Com (NYSE:EMR) by 107,242 shares to 138,939 shares, valued at $8.30 million in 2018Q4, according to the filing. It also increased its holding in Comcast Corp New Cl A (NASDAQ:CMCSA) by 9,618 shares in the quarter, for a total of 368,146 shares, and has risen its stake in Alphabet Inc Cap Stk Cl A.

Since October 19, 2018, it had 2 insider buys, and 5 selling transactions for $4.86 million activity. $317,310 worth of JPMorgan Chase & Co. (NYSE:JPM) was sold by Friedman Stacey on Tuesday, January 29. Another trade for 13,341 shares valued at $1.40 million was made by Beer Lori A on Tuesday, January 29. BACON ASHLEY sold $599,304 worth of stock. 11,659 shares valued at $1.22M were sold by Petno Douglas B on Tuesday, January 29. On Tuesday, January 29 Scher Peter sold $1.96M worth of JPMorgan Chase & Co. (NYSE:JPM) or 18,679 shares. The insider CROWN JAMES S bought $518,950.

Investors sentiment increased to 1 in Q4 2018. Its up 0.05, from 0.95 in 2018Q3. It is positive, as 71 investors sold JPM shares while 735 reduced holdings. 135 funds opened positions while 667 raised stakes. 2.33 billion shares or 0.45% more from 2.32 billion shares in 2018Q3 were reported. Forte Lc Adv invested 0.77% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). 10 has invested 3.31% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Louisiana State Employees Retirement Sys, a Louisiana-based fund reported 174,400 shares. Raymond James & Associate reported 5.86M shares stake. Money Mgmt Limited Liability Corporation owns 2.54% invested in JPMorgan Chase & Co. (NYSE:JPM) for 41,346 shares. 88,276 are owned by Tam. State Of New Jersey Common Pension Fund D has invested 1.78% in JPMorgan Chase & Co. (NYSE:JPM). Lloyds Plc has 26.45% invested in JPMorgan Chase & Co. (NYSE:JPM). Truepoint invested 0.04% in JPMorgan Chase & Co. (NYSE:JPM). Beese Fulmer Invest Mngmt reported 62,035 shares. Moreover, Arizona State Retirement System has 0.97% invested in JPMorgan Chase & Co. (NYSE:JPM) for 775,212 shares. Ftb Advsr Inc stated it has 1% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Kempen Cap Mgmt Nv holds 0.34% or 31,377 shares. Tuttle Tactical Management has invested 1.49% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). Bokf Na accumulated 352,749 shares.

More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: Investorplace.com which released: “3 Reasons JP Morgan Is a Solid Blue-Chip Play – Investorplace.com” on March 15, 2019, also Seekingalpha.com with their article: “JPMorgan adds to BetaBuilders ETF line – Seeking Alpha” published on March 11, 2019, Seekingalpha.com published: “Politics And Markets Collide: JPMorgan Cuts Ties With Private Prisons, Impacting GEO Group And CoreCivic – Seeking Alpha” on March 13, 2019. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: Gurufocus.com and their article: “JP Morgan Asset Management Announces Liquidation of Two Exchange-Traded Funds – GuruFocus.com” published on March 06, 2019 as well as Seekingalpha.com‘s news article titled: “JPMorgan: Buy Or Sell? – Seeking Alpha” with publication date: February 25, 2019.

JPMorgan Chase & Co. (NYSE:JPM) Institutional Positions Chart